Prognosis Prediction of Measurable Enhancing Lesion after Completion of Standard Concomitant Chemoradiotherapy and Adjuvant Temozolomide inGlioblastoma Patients: Application of Dynamic Susceptibility ContrastPerfusion and Diffusion-Weighted Imaging
Cited 8 time in
Cited 10 time in
1,596 Viewed
297 Downloaded
-
Title
- Prognosis Prediction of Measurable Enhancing Lesion after Completion of Standard Concomitant Chemoradiotherapy and Adjuvant Temozolomide inGlioblastoma Patients: Application of Dynamic Susceptibility ContrastPerfusion and Diffusion-Weighted Imaging
-
Author(s)
- Kim, JH; Seung Hong Choi; Ryoo, I; Yun, TJ; Kim, TM; Lee, SH; Park, CK; Kim, JH; Sohn, CH; Park, SH; Kim, IH
-
Publication Date
- 2014-11
-
Journal
- PLOS ONE, v.9, no.11, pp.e113587
-
Publisher
- PUBLIC LIBRARY SCIENCE
-
Abstract
- To assess the prognosis predictability of a measurable enhancing lesion
using histogram parameters produced by the normalized cerebral blood volume
(nCBV) and normalized apparent diffusion coefficient (nADC) after completion of
standard concomitant chemoradiotherapy (CCRT) and adjuvant temozolomide
(TMZ) medication in glioblastoma multiforme (GBM) patients.
Materials and Methods: This study was approved by the institutional review board
(IRB), and the requirement for informed consent was waived. A total of 59 patients
with newly diagnosed GBM who received standard CCRT with TMZ and adjuvant
TMZ for six cycles underwent perfusion-weighted and diffusion-weighted imaging.
Twenty-seven patients had a measurable enhancing lesion and 32 patients lacked
a measurable enhancing lesion based on the Response Assessment in Neuro-
Oncology (RANO) criteria in the follow-up MRI, which was performed within 3months after adjuvant TMZ therapy was completed. We measured the nCBV and
nADC histogram parameters based on the measurable enhancing lesion. The
progression free survival (PFS) was analyzed by the Kaplan-Meier method with the
use of the log-rank test.
Results: The median PFS of patients lacking measurable enhancing lesion was
longer than for those with measurable enhancing lesions (17.6 vs 3.3 months,
P,.0001). There was a significant, positive correlation between the 99th percentile
nCBV value of a measurable enhancing lesion and the PFS (P5.044, R25.152). In
addition, the median PFS was longer in patients with a 99th percentile nCBV value
§4.5 than it was in those with a value ,4.5 (4.4 vs 3.1 months, P5.036).
Conclusion: We found that the nCBV value can be used for the prognosis
prediction of a measurable enhancing lesion after the completion of standard
treatment for GBM, wherein a high 99th percentile nCBV value (§4.5) suggests a
better PFS for GBM patients.
-
URI
- https://pr.ibs.re.kr/handle/8788114/875
-
DOI
- 10.1371/journal.pone.0113587
-
ISSN
- 1932-6203
-
Appears in Collections:
- Center for Nanoparticle Research(나노입자 연구단) > 1. Journal Papers (저널논문)
- Files in This Item:
-
Prognosis Prediction of Measurable Enhancing Lesion after.pdfDownload
-
- Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.